Humoral and cellular responses to SARS‐CoV ‐2 in patients with B‐cell haematological malignancies improve with successive vaccination
British Journal of Haematology · 2023
DOI: 10.1111/bjh.18962 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Christopher L Pinder und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infection and Immunity, University College London, London, UK. Hauptthemen laut MEDLINE: COVID-19, Hematologic Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, Department of Health, Wellcome Trust.
Abstract (Originalsprache)
Patients with haematological malignancies are more likely to have poor responses to vaccination. Here we provide detailed analysis of the humoral and cellular responses to COVID‐19 vaccination in 69 patients with B‐cell malignancies. Measurement of anti‐spike IgG in serum demonstrated a low seroconversion rate with 27.1% and 46.8% of patients seroconverting after the first and second doses of vaccine, respectively. In vitro pseudoneutralisation assays demonstrated a poor neutralising response, with 12.5% and 29.5% of patients producing a measurable neutralising titre after the first and second doses, respectively. A third dose increased seropositivity to 54.3% and neutralisation to 51.5%, while a fourth dose further increased both seropositivity and neutralisation to 87.9%. Neutralisation titres post‐fourth dose showed a positive correlation with the size of the B‐cell population measured by flow cytometry, suggesting an improved response correlating with recovery of the B‐cell compartment after B‐cell depletion treatments. In contrast, interferon gamma ELISpot analysis showed a largely intact T‐cell response, with the percentage of patients producing a measurable response boosted by the second dose to 75.5%. This response was maintained thereafter, with only a small increase following the third and fourth doses, irrespective of the serological response at these timepoints.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Infection and Immunity, University College London, London, UK.
- Department of Clinical Haematology, University College London Hospitals, NHS Foundation Trust, London, UK.
- CR UK and UCL Cancer Trials Centre, UCL Cancer Institute, UCL, London, UK.
ORCID-Profile: Christopher L Pinder, Thomas A Fox, Laura E McCoy
Förderung
- Medical Research Council
- Department of Health
- Wellcome Trust
- University College London Hospitals NHS Foundation Trust
Zitieren
APA
Pinder, C. L., Jankovic, D., Fox, T. A., Kirkwood, A., Enfield, L., Alrubayyi, A., Touizer, E., Ford, R., Pocock, R., Shin, J. S., Ziegler, J., Thomson, K. J., Ardeshna, K. M., Peppa, D., McCoy, L. E., & Morris, E. C. (2023). Humoral and cellular responses to SARS‐CoV ‐2 in patients with B‐cell haematological malignancies improve with successive vaccination. British Journal of Haematology. https://doi.org/10.1111/bjh.18962
Vancouver
Pinder CL, Jankovic D, Fox TA, Kirkwood A, Enfield L, Alrubayyi A, et al. Humoral and cellular responses to SARS‐CoV ‐2 in patients with B‐cell haematological malignancies improve with successive vaccination. British Journal of Haematology. 2023. doi:10.1111/bjh.18962
BibTeX
@article{Pinder2023,
author = {Pinder, Christopher L and Jankovic, Dylan and Fox, Thomas A and Kirkwood, Amy and Enfield, Louise and Alrubayyi, Aljawharah and Touizer, Emma and Ford, Rosemarie and Pocock, Rachael and Shin, Jin-Sup and Ziegler, Joseph and Thomson, Kirsty J and Ardeshna, Kirit M and Peppa, Dimitra and McCoy, Laura E and Morris, Emma C},
title = {Humoral and cellular responses to SARS‐CoV ‐2 in patients with B‐cell haematological malignancies improve with successive vaccination},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.18962}
}
EUVIMED